Dr. Ioana Bonta
Claim this profileNorthside Hospital
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
5 reported clinical trials
11 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage II
2Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Ioana Bonta is currently running
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
More about Ioana Bonta
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Ioana Bonta has experience with
- Carboplatin
- Pembrolizumab
- Nivolumab-relatlimab FDC
- Regorafenib
- TAS-102
- Gemcitabine Hydrochloride
Breakdown of trials Ioana Bonta has run
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ioana Bonta specialize in?
Ioana Bonta focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Ioana Bonta currently recruiting for clinical trials?
Yes, Ioana Bonta is currently recruiting for 2 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that Ioana Bonta has studied deeply?
Yes, Ioana Bonta has studied treatments such as Carboplatin, Pembrolizumab, Nivolumab-relatlimab FDC.
What is the best way to schedule an appointment with Ioana Bonta?
Apply for one of the trials that Ioana Bonta is conducting.
What is the office address of Ioana Bonta?
The office of Ioana Bonta is located at: Northside Hospital, Atlanta, Georgia 30342 United States. This is the address for their practice at the Northside Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.